![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sustained Virological Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
AASLD: Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver Transplantation - (11/06/13)
AASLD: Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study - (11/05/13)
AASLD: Initial Evaluation of the Sofosbuvir Compassionate Use Program for Patients With Severe Recurrent HCV Following Liver Transplantation - (11/06/13)
A Coilly, J Dumortier, D Botta-Fridlund, M Latournerie, V Leroy, GP. Pageaux, E Giostra, C Moreno, B Roche, TM Antonini, H Agostini, P Lebray, S Radenne, AC Saouli, Y Calmus, L Alric, M Debette-Gratien, V De Ledinghen, F Durand, C Duvoux, D Samuel, JC Duclos-Vallee
![AASLD1.gif](../images/111813/111813-6/AASLD1.gif)
![AASLD2.gif](../images/111813/111813-6/AASLD2.gif)
![AASLD3.gif](../images/111813/111813-6/AASLD3.gif)
![AASLD4.gif](../images/111813/111813-6/AASLD4.gif)
![AASLD5.gif](../images/111813/111813-6/AASLD5.gif)
![AASLD6.gif](../images/111813/111813-6/AASLD6.gif)
![AASLD7.gif](../images/111813/111813-6/AASLD7.gif)
![AASLD8.gif](../images/111813/111813-6/AASLD8.gif)
![AASLD9.gif](../images/111813/111813-6/AASLD9.gif)
![AASLD10.gif](../images/111813/111813-6/AASLD10.gif)
![AASLD11.gif](../images/111813/111813-6/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|